Differences in plasma gastrin, CEA, and CA 19-9 concentration in patients with proximal and distal colorectal cancer

International Journal of Gastrointestinal Cancer

Volumn 31, Issue 1-3, 2002, Pages 155-163

  Bombski, Grzegorz ^a   Gasiorowska, Anita ^b   Orszulak Michalak, Daria ^b   Neneman, Beata ^a   Kotynia, Justyna ^b   Strzelczyk, Janusz ^b   Janiak, Adam ^b   Malecka Panas, Ewa ^b  

^a Regional Hospital   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

CA 19 9; CEA; Distal colorectal cancer; Gastrin; Proximal colorectal cancer

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GASTRIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 0036937847     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:31:1-3:155     Document Type: Article

References (64)

1. Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000;47:820-824.
2. Singh P, Owila A, Varro A, et al. Gastrin gene expression is required for the proliferation and tumorigenicity of human colon cancer cells. Cancer Res 1996;56:4111-4115.
3. Guo YS, Baijal M, Jin GF, et al. Growth-promoting effects of gastrin on mouse colon cancer cells in vitro: absence of autocrine efects. In Vitro Cell Dev Biol 1990;26:871-877.
4. Boland CR. Gastrin and colorectal neoplasia - chicken or egg or both? [Editorial]. J Clin Gastroenterol 1991;13:497-499.
5. Saurin JC, Rouault JP, Abello J, et al. High gastrin releasing peptide receptor mRNA level is related to tumor dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur J Cancer 1999;35:125-132.
6. Singh P, Xu Z, Dai B, et al. Incomplete processing of progastrin expressed by human colon cancer cells: role of noncarboxyamidated gastrins. Am J Physiol 1994;266:G459-G468.
7. Hartwich A, Konturek SJ, Pierzchalski P, et al. Helicobacter infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer. Int J Colorectal Dis 2001;16:202-210.
8. Watson SA, Durrant LG, Crosbie JD, et al. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer 1989;43:692-696.
9. Imdahl A, Eggstein S, Crone C, et al. Growth of colorectal carcinoma cells: regulation in vitro by gastrin, pentagastrin and the gastrin receptor antagonist proglumide. J Cancer Res Clin Oncol 1989;115:388-392.
10. D'Agostino L, Pignata S, Tritto G, et al. Hypergastrinemia in rats with azoxymethane-induced colon cancers. Int J Cancer 1995;61:223-226.
11. Watson SA, Michaeli D, Morris TM, et al. Antibodies raised by gastrimmune inhibit the spontaneous metastasis of human colorectal tumor AP5LV. Eur J Cancer 1999;35:1286-1291.
12. Warson SA, Clifford T, Sykes RE, et al. Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism. Eur J Cancer 1995;31:2086-2092.
13. Romani R, Howes LG, Morris DL. Dose dependent in vivo inhibition of human colorectal cancer (LoVo) by the gastrin receptor antagonist, CI-988. Clin Exp Pharmacol Physiol 1996;438-440.
14. Renga M, Brandi G, Paganelli GM, et al. Rectal cell proliferation and colon cancer risk in patients with hypergastrinemia. Gut 1997;41:330-332.
15. Malecka-Panas E, Fligiel J, Majumdar APN. Differential responsiveness of proximal and distal colonic mucosa to gastrin. Peptides 1997;18:559-565.
16. Malecka-Panas E, Tureaud J, Majumdar APN. Gastrin activates tyrosine kinase (Tyr-k) and phospholipase C (PLC) in isolated rat colonocytes. Acta Biochimica Polonica 1996;43:539-546.
17. Charnley RM, Thomas WM, Stanley J, et al. Serum gastrin concentrations in colorectal cancer patients. Ann R Coll Surg Engl 1992;74:138-140.
18. Karlin DA, McBath M, Jones RD, et al. Hypergastrinemia and colorectal carcinogenesis in the rat. Cancer Lett 1985;29:73-78.
19. Watson SA, Smith AM. Hypergastrinemia promotes adenoma progression in the APC (Min+/-) mouse model of familial adenomatous polyposis. Cancer Res 2001;61:625-631.
20. Begos DG, Modlin IM. Gastrin and colorectal cancer. Clarifying the controversy. J Clin Gastroenterol 1994;18:189-193.
21. Garnett WR. Considerations for long-term use of proton-pump inhibitors. Am J Health Syst Pharm 1998;55:2279-2286.
22. Wong K, Beardshall K, Waters CM, et al. Postprandial hypergastrinemia in patients with colorectal cancer. Gut 1991;32:1352-1354.
23. Mihas AA, Maliakkal RJ, Shueke M, et al. Serum gastrin levels in patients with colorectal cancer and adenomatous polyps: a prospective study. Res Commun Mol Pathol Pharmacol 1995;90:301-304.
24. Yapp RG, Modlin IM, Kumar RR, et al. Gastrin and colorectal cancer: evidence against an association. Dig Dis Sci 1992;37:481-484.
25. Penman ID, El-Omar E, Ardill JE, et al. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology 1994;106:1263-1270.
26. Orbuch M, Venzon DJ, Lubensky IA, et al. Prolonged hypergastrinemia does not increase the frequency of colonic neoplasia in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1996;41:604-613.
27. Seitz JF, Giovannini M, Monges G, et al. Serum gastrin levels in colorectal cancers. Evolution after treatment. Gastroenterol Clin Biol 1992;16:385-387.
28. Langman J. Medical Embryology, 4th ed. Williams & Wilkins, Baltimore, MD, 1981
29. Sato M, Ahnen DJ. Regional variability of colonocyte growth and differentiation in the rat. Anat Rec 1992;233:409-412.
30. Shioda Y, Brown WR, Ahnen DJ. Serial observation of colonic carcinogenesis in the rat. Premalignat mucosa binds Ulex europeus aglutinin. Gastroenterology 1987;92:1-8.
31. Lothe RA, Peltomaaki P, Meling GI. Genomic instability in colorectal cancer. Relationship to clinicopathological variables in family history. Cancer Res 1993;53:5849-5852.
32. Kim H, Jen J, Vogelstein B, et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:148-151.
33. Bulfill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal and distal tumor location. Ann Intern Med 1990;113:779-788.
34. Elsaleh H, Joseph G, Grieu F, et al. Association of tumor site and sex with survival benefit from adjuvant chemotherapy of colorectal cancer. Lancet 2000;355:1745-1750.
35. Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998;115:275-280.
36. von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of tumor markers, Ca 242, CA 19-9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325-2331.
37. Lindmark G, Bergstrom R, Pahlman L, et al. The association of preoperative serum tumour markers with Dukes stage and survival in colorectal cancer. Br J Cancer 1995;71:1090-1094.
38. Nahachai V, Walker K, Sevelius H, et al. Antisecretory and serum gastrin lowering effect of endoprostil in patients with duodenal ulcer disease. Proc Natl Acad Sci USA 1987;84:7188-7192.
39. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 1993;104:1356-1370.
40. Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. Cancer 1993;71:745-750.
41. Peach HG, Barnett NE. Determinants of basal plasma gastrin levels in the general population. J Gastroenterol Hepatol 2000;15:1267-1271.
42. Smith AM, Watson SA, Caplin M, et al. Gastric carcinoid expresses the gastrin autocrine pathway. Br J Surg 1998;85:1285-1289.
43. Hollande F, Imdahl A, Mantamadiotis T. Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. Gastroenterology 1997;113:1576-1588.
44. Rehfeld JF. Gastrin and colorectal cancer: a never-ending dispute? Gastroenterology 1995;108:1307-1310
45. Watson SA, Durrant LG, Morris DL. Gastrin: growth enhancing effects on human gastric and colonic tumor cells. Br J Cancer 1989;59:554-558.
46. Hoosein NM, Kiener PA, Curry RC, et al. Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/ cholecystokinin-like peptide. Exp Cell Res 1990;186:15-21.
47. Wu J, Rao GN, Dai B, et al. Autocrine gastrins in colon cancer cells up-regulate cytochrom c oxidase Vb and down-regulate efflux of cytochrome c and activation of caspase-3. J Biol Chem 2000;275:32,491-32,498.
48. Singh P, Walker JP, Townsend CM, et al. Role of gastrin and gastrin receptors on the growth of transplantable mouse colon carcinoma (MC-26) in BALB/c mice. Cancer Res 1986;46:1612-1616.
49. Kermorgant S, Lehy T. Glycine-extended gastrin promotes the invasiveness of human colon cancer cells. Biochem Biophys Res Commun 2001;285:136-141.
50. Smith JP, Solomon TE. Effects of gastrin, proglumide and somatostatin on growth of human colon cancer. Gastroenterology 1988;95:1541-1548.
51. Ciccotosto GD, McLeish A, Hardy KJ, et al. Expression, processing and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 1995;9:1142-1153.
52. Fontanesi BV, Boris B, Delcio M, et al. Gastrin levels in patients with colorectal cancer. Hepato-Gastroenterology 1997;4:1082-1084.
53. Kikendall JW, Glass AR, Sobin LH, et al. Serum gastrin is not higher in subjects with colonic neoplasia. Am J Gastroenterol 1992;7:1394-1397.
54. Smith JP, Solomon TE, Wood JG. Elevated gastrin levels in patients with colon carcinomas or adenomatous polyps. Dig Dis Sci 1989;34:171-174.
55. Upp JR, Singh P, Townsend CM, et al. Clinical significance of gastrin receptors in human colon cancers. Cancer Res 1989;49:488-492.
56. Kameyama M, Fukuda I, Imaoka S, et al. Level of serum gastrin as a predictor of liver metastasis from colorectal cancer. Dis Colon Rectum 1993;36:497-500.
57. Vanderstraeten EF, De Vos MM, Versieck JM, et al. Serum gastrin levels and colorectal neoplasia. Dis Colon Rectum 1995;38:172-176.
58. Martin EW, Kibbey WE, DiVecchia L, et al. Carcinoembryonic antigen clinical and histological aspects. Cancer 1976;37:62-81.
59. Livingstone AS, Hampson LG, Shuster J, et al. Carcinoembryonic antigen in the diagnosis and management of colorectal carcinoma. Arch Surg 1974;109:259-264.
60. Carpelan-Holmstrom, Haglund CH, Robets PJ. Differences in serum tumor markers between colon and rectal cancer: comparison of CA 242 and carcinoembryonic antigen. Dis Col Rectum 1996;39:799-805.
61. Joint Cancer National Insitute of Canada/American Cancer Society Investigation. A collaborative study of a test for carcinoembryonic antigen (CEA) in the sera of patients with carcinoma of the colon and rectum. Can Med Assoc J 1972;107:5-33.
62. Thomas P, Zamcheck N. Role of the liver in clearance and exertion of circulating carcinoembryonic antigen (CEA). Dig Dis Sci 1983;28:216-224.
63. Tatsuta M, Yamamura H, Iishi H, et al. Values of CA19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985;56:2669-2673.
64. Schmiegel WH, Kreiker C, Eberl W, et al. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut 1985;26:456-460.